{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-24-000034","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.781911+00:00","generated_at":"2026-05-30T01:52:32.886472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena reports Q3 net loss of $59M on $1M revenue, cash at $520M; pipeline readouts expected in 2024-2025","bullets":["Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.","Cash and restricted cash $520.1M as of Sep 30 2024; full-year net cash use guidance reaffirmed at $148-$160M.","Expects topline results from Phase 2b PADOVA (prasinezumab) in 4Q2024 and Phase 3 AFFIRM-AL (birtamimab) in 1H2025.","Phase 1 ASCENT trials (PRX012) for Alzheimer's disease to report multiple readouts starting mid-2025.","Appointed Chad J. Swanson, Ph.D., as Chief Development Officer in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-24-000034","json":"https://secwatch.observer/filing/0001559053-24-000034.json","markdown":"https://secwatch.observer/filing/0001559053-24-000034.md","text":"https://secwatch.observer/filing/0001559053-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/0001559053-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/prta-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:52:32.886472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}